Final overall survival results from the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel reduced the risk of death versus nab-paclitaxel alone in platinum-resistant ovarian cancer. The reported hazard ratio was 0.65, and median overall survival improved to 16.0 months from 11.9 months. The update included survival rates at 12 and 18 months and indicated benefits across prespecified subgroups, including prior PARP exposure and platinum-free interval length. The piece also states the regimen received FDA approval in March 2026 and is now listed as a preferred option in NCCN guidelines. Clinicians are likely to focus on how the outcome data support positioning for second-line and later use, and whether uptake accelerates given the guideline status.